


Supplementary Table 1. Variables of the Group B cases of whose most symptomatic joint is included in the 28 joints of DAS28 and not included in the 28 joints

Variable	Included in the 28 joints (Group B-1; <i>n</i> = 116)		Not included in the 28 joints (Group B-2; <i>n</i> = 32)		<i>p</i> -Value
Age (year)	61.1 ± 13.7	(<i>n</i> = 116)	58.3 ± 14.5	(<i>n</i> = 32)	0.33
Sex (F/(M+F) (%))	82	(<i>n</i> = 116)	91	(<i>n</i> = 32)	0.29
RF positive (%)	84	(<i>n</i> = 115)	84	(<i>n</i> = 32)	1
ACPA positive (%)	78	(<i>n</i> = 107)	68	(<i>n</i> = 25)	0.31
Swollen joint count	3.21 ± 3.29	(<i>n</i> = 113)	3.28 ± 4.37	(<i>n</i> = 29)	0.93
Tender joint count	4.12 ± 4.57	(<i>n</i> = 113)	3.34 ± 4.10	(<i>n</i> = 29)	0.41
PGA (mm)	39.4 ± 25.4	(<i>n</i> = 101)	37.3 ± 25.8	(<i>n</i> = 26)	0.71
CRP (mg/dl)	0.80 ± 1.60	(<i>n</i> = 114)	0.55 ± 1.23	(<i>n</i> = 31)	0.43
ESR (mm/h)	28.8 ± 26.1	(<i>n</i> = 107)	18.0 ± 22.1	(<i>n</i> = 29)	0.045*
DAS28-CRP	3.33 ± 1.20	(<i>n</i> = 101)	2.95 ± 1.45	(<i>n</i> = 26)	0.16
DAS28-ESR	3.90 ± 1.50	(<i>n</i> = 96)	2.99 ± 1.70	(<i>n</i> = 25)	9.8 × 10 ⁻³ **
Total PD score-8	3.58 ± 4.21	(<i>n</i> = 116)	2.59 ± 3.21	(<i>n</i> = 32)	0.22
Total GS score-8	6.02 ± 4.69	(<i>n</i> = 116)	4.88 ± 3.30	(<i>n</i> = 32)	0.20

p* < 0.05, *p* < 0.01.

Supplementary Table 2. Variables of the Group B cases of which 8-joint US assessment is negative with positive and negative result of additional assessment

Variable	Additional assessment Positive (<i>n</i> = 13)		Additional assessment Negative (<i>n</i> = 21)		<i>p</i> -Value
Age (year)	58.2 ± 14.7	(<i>n</i> = 13)	57.7 ± 12.6	(<i>n</i> = 21)	0.91
Sex (F/(M+F) (%))	85	(<i>n</i> = 13)	76	(<i>n</i> = 21)	0.68
RF positive (%)	62	(<i>n</i> = 13)	75	(<i>n</i> = 20)	0.46
ACPA positive (%)	58	(<i>n</i> = 12)	67	(<i>n</i> = 18)	0.71
Swollen joint count	1.17 ± 1.64	(<i>n</i> = 12)	1.20 ± 0.47	(<i>n</i> = 20)	0.47
Tender joint count	2.17 ± 2.29	(<i>n</i> = 12)	3.00 ± 3.35	(<i>n</i> = 20)	0.45
PGA (mm)	39.4 ± 22.2	(<i>n</i> = 12)	28.8 ± 21.4	(<i>n</i> = 20)	0.21
CRP (mg/dl)	0.14 ± 0.17	(<i>n</i> = 12)	0.22 ± 0.30	(<i>n</i> = 20)	0.40
ESR (mm/h)	11.6 ± 13.0	(<i>n</i> = 12)	13.0 ± 12.9	(<i>n</i> = 20)	0.77
DAS28-CRP	2.62 ± 0.95	(<i>n</i> = 12)	2.57 ± 0.88	(<i>n</i> = 17)	0.88
DAS28-ESR	2.68 ± 1.50	(<i>n</i> = 12)	2.84 ± 1.20	(<i>n</i> = 17)	0.75
Total PD score-8	0.00 ± 0.00	(<i>n</i> = 13)	0.00 ± 0.00	(<i>n</i> = 21)	-
Total GS score-8	1.77 ± 1.64	(<i>n</i> = 13)	1.76 ± 1.87	(<i>n</i> = 21)	0.99



Supplementary Figure 1. Comparison with US findings in the most symptomatic joint among the routine 8 joints with those in the most symptomatic joint among other joints.

(a, b) Correlation diagrams between GS scores in the most symptomatic joints and the 8-joint scores in the symptomatic group; (a) Group A ($n = 209$), (b) Group B ($n = 148$). Spearman's correlation coefficients (r_s) are shown above each diagram. (c) Correlation diagrams between PD or GS scores in the most symptomatic joints and those in the other 7 routine assessment joints in Group A ($n = 209$).